Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Risk | Very High | Very High |
Rating | 2.0 | 4.0 |
Min SIP Amount | ₹100 | ₹100 |
Expense Ratio | 1.84 | 2.2 |
NAV | ₹718.71 | ₹101.59 |
Fund Started | 16 Dec 1993 | 25 Mar 1997 |
Fund Size | ₹7384.10 Cr | ₹1072.74 Cr |
Exit Load | Exit load of 1% if redeemed within 1 year | Exit load of 1%, if redeemed within 30 days. |
Risk
Rating
Min SIP Amount
Expense Ratio
NAV
Fund Started
Fund Size
Exit Load
1 Year | 22.34% | 24.98% |
3 Year | 17.47% | 24.55% |
5 Year | 20.01% | 24.63% |
1 Year
3 Year
5 Year
Equity | 99.31% | 99.31% |
Cash | 0.69% | 0.69% |
Equity
Cash
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
---|---|
ICICI Bank Ltd. | 7.22% |
HDFC Bank Ltd. | 6.93% |
Infosys Ltd. | 4.72% |
Bharti Airtel Ltd. | 4.30% |
Axis Bank Ltd. | 3.92% |
State Bank of India | 3.75% |
NTPC Ltd. | 3.05% |
Larsen & Toubro Ltd. | 2.77% |
Sun Pharmaceutical Industries Ltd. | 2.65% |
HCL Technologies Ltd. | 2.38% |
Name | Assets |
---|---|
HDFC Bank Ltd. | 7.21% |
Infosys Ltd. | 4.57% |
ICICI Bank Ltd. | 4.12% |
Dr. Reddy's Laboratories Ltd. | 3.14% |
State Bank of India | 2.74% |
NTPC Ltd. | 2.64% |
REC Ltd. | 2.49% |
Tech Mahindra Ltd. | 2.23% |
Amber Enterprises India Ltd. | 2.16% |
Suven Pharmaceuticals Ltd. | 2.07% |
Name | Gopal Agrawal | Satish Ramanathan |
Start Date | 29 Jul 2022 | 01 Oct 2024 |
Name
Start Date
Description | The scheme seeks to achieve capital appreciation/income in the long term by primarily investing in undervalued stocks. | The scheme aims to provide long term capital growth by investing primarily in a well-diversified portfolio of undervalued securities. |
Launch Date | 16 Dec 1993 | 25 Mar 1997 |
Description
Launch Date